Clean Air Metals Announces a Mineral Resource for the Thunder Bay North Project including a total Indicated Resource of 16,285,396 tonnes at an average grade of 3.5 g/t PdEq containing 1,834,158 ounces PdEq and a total Inferred Resource of 9,852,138 tonnes at an average grade of 2.1 g/t PdEq containing 663,660 ounces PdEq

PR Newswire

THUNDER BAY, ON, Jan. 20, 2021 /PRNewswire/ – Clean Air Metals Inc. (Clean Air Metals” or the Company“) (TSXV: AIR) (OTCQB: CLRMF) (FRA: CKU) is pleased to announce that the Company has released an updated Indicated and Inferred mineral resource estimate prepared in accordance with National Instrument 43-101 (“NI 43-101″) for the Company’s 100%-owned Thunder Bay North Project (the “Project“) which includes both the Current Lake and Escape Lake deposits.

The mineral resource estimate was prepared by Nordmin Engineering Ltd. (“Nordmin“) and is based on an underground ramp-access constrained resource model with a cutoff value equating to 1.56 g/tonne PdEq (2.56 g/tonne PtEq) using 3-year trailing average metal prices for all metals except cobalt, which used a 2-year trailing average as described below in Table 8. A technical report will be filed on SEDAR within 45 days of the date of this news release.

The Current Lake Deposit contains an Indicated mineral resource of 11,999,177 tonnes grading 3.44 g/t PdEq and an Inferred mineral resource of 6,406,960 tonnes grading 2.02 g/tonne PdEq (See Table 1; Figure 2).

The Escape Lake Deposit contains an Indicated mineral resource of 4,286,220 tonnes grading 3.67 g/t PdEq and an Inferred mineral resource of 3,445,179 tonnes grading 2.23 g/tonne PdEq (See Table 2; Figure 3).


Highlights

  • Indicated mineral resources at Thunder Bay North Project are approximately 1.33 million oz PdEq in the Current Lake Deposit and 0.50 million oz PdEq in the Escape Lake Deposit.
  • Inferred mineral resources at Thunder Bay North Project are approximately 0.41 million oz PdEq in the Current Lake Deposit and 0.25 million oz PdEq in the Escape Lake Deposit.
  • The underground resource at the Current Lake Deposit will now be the focus of a Preliminary Economic Assessment which will include specific work on geotechnical analysis and bench scale testing on a drilled bulk sample of mineralized material to verify metallurgical recoveries.
  • The Indicated mineral resource is developed in multiple zones which exhibit a variable grade profile with highest grades occurring at relatively shallow depths, including the lower Current Zone and Bridge Zone in the Current Lake Deposit. (See Table 3; Figure 1).
  • The initial mineral resource at Escape Lake is geologically open and will be the target of an extensive systematic drilling program planned for 2021.
  • Current Lake and Escape Lake are polymetallic deposits with a roughly 1:1 platinum to palladium ratio and comparable geological attributes and metal grades.
  • Nickel and Copper contribute significant metal values and will be tested for metallurgical flotation and recovery potential.
  • Gold, Silver, Cobalt and Rhodium are potentially valuable byproducts in the metal mix at Thunder Bay North Project.


Table 1: Thunder Bay North Project – Grade Summary


Grade


Category


Tonnes


Pt (g/t)


Pd
(g/t)


Au
(g/t)


Ag
(g/t)


Rh
(g/t)


Co
(g/t)


Cu (%)


Ni (%)


PtEq 
(g/t)


PdEq
(g/t)

Indicated – Current Lake

11,999,177

1.48

1.40

0.07

1.32

0.04

137

0.28

0.17

5.79

3.44

Indicated – Escape Lake

4,286,220

0.92

1.18

0.12

2.45

0.06

209

0.52

0.28

6.16

3.67


TOTAL INDICATED RESOURCE


16,285,396


1.33


1.34


0.08


1.62


0.05


156


0.34


0.20


5.89


3.50

Inferred – Current Lake

6,406,960

0.68

0.65

0.06

0.95

0.01

123

0.30

0.14

3.40

2.02

Inferred – Escape Lake

3,445,179

0.64

0.73

0.07

1.13

0.00

173

0.33

0.18

3.75

2.23


TOTAL INFERRED RESOURCE


9,852,138


0.67


0.68


0.07


1.01


0.01


140


0.31


0.15


3.52


2.10


Notes: See section “Input Parameters for Resource Calculation” below. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability.


Table 2: Thunder Bay North Project – Contained Metal


Metal


Category


Tonnes


Pt (Oz)


Pd (Oz)


Au
(Oz)


Ag (Oz)


Rh (Oz)


Co
(Tonnes)


Cu
(Tonnes)


Ni
(Tonnes)


PtEq 
(Oz)


PdEq 
(Oz)

Indicated – Current Lake

11,999,177

569,176

538,181

26,121

508,434

16,998

1,649

33,751

20,969

2,233,575

1,328,789

Indicated – Escape Lake

4,286,220

127,090

162,337

16,928

337,946

8,009

896

22,390

12,016

849,481

505,369


TOTAL INDICATED RESOURCE


16,285,396


696,266


700,517


43,050


846,380


25,008


2,544


56,141


32,985


3,083,056


1,834,158

Inferred – Current Lake

6,406,960

140,400

133,333

12,888

195,484

1,836

785

19,155

9,113

700,621

416,810

Inferred – Escape Lake

3,445,179

70,520

80,989

7,754

124,809

71

595

11,293

6,046

414,932

246,850


TOTAL INFERRED RESOURCE


9,852,138


210,919


214,322


20,642


320,293


1,907


1,380


30,449


15,159


1,115,553


663,660


Notes: See section “Input Parameters for Resource Calculation” below. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability.


Webinar

Clean Air Metals will be conducting a webinar to discuss the resource update with Amvest Capital on January 26th at 4:05pm EST. Please see the link below:

Link: https://attendee.gotowebinar.com/register/3724157345636755725?source=co


Executive Comments


Abraham Drost,

P.Geo.
,
 
CEO of Clean Air Metals stated, “We are very pleased for our shareholders and participating First Nations with this milestone mineral resource study. An underground ramp-access mine planning approach by Nordmin Engineering has been the key to unlock value at the Thunder Bay North Project. We look forward to a busy year ahead as we continue drilling with two drills in an effort to increase and upgrade mineral resources at the Escape Lake. We also plan on adding a drill at the Current Lake Deposit focused on upgrading Inferred material to Indicated and testing nearby greenfields exploration targets with massive sulphide potential.” 


Jim Gallagher, P.Eng., Executive Chairman of Clean Air Metals
 stated, “The broad suite of metals contained in the Thunder Bay North deposits is quite unique and positions the Company well for participation in the transition to a low carbon transportation future. Tougher emissions standards worldwide have significantly increased loadings of Palladium and Rhodium in auto catalysts pushing prices to near record levels. Platinum prices have risen sharply in the last several months as hydrogen and fuel cells become a viable alternative especially in the trucking and long-distance transportation sectors. Nickel, Copper and Cobalt are key to the battery electric revolution and Gold and Silver provide a potential sweetener to a future revenue stream. Subject to future feasibility studies around economic viability, this could give Clean Air Metals a natural hedge against fluctuating metal prices regardless of which technology becomes dominant.”


Table 3: Current Lake Deposit – Grade Summary


Grade


Category


Area


Tonnes


Pt
(g/t)


Pd
(g/t)


Au
(g/t)


Ag
(g/t)


Rh
(g/t)


Co
(g/t)


Cu
(%)


Ni
(%)


PtEq
(g/t)


PdEq
(g/t)

Indicated – Current Lake

Upper Current

1,089,212

1.60

1.50

0.08

1.72

0.07

148

0.35

0.20

6.50

3.87

Current

1,534,911

2.10

1.96

0.11

2.25

0.05

142

0.41

0.21

7.97

4.74

Bridge

3,355,050

1.72

1.67

0.08

1.49

0.05

130

0.35

0.17

6.67

3.97

Beaver

4,481,507

1.23

1.14

0.05

1.00

0.03

139

0.20

0.16

4.82

2.87

Cloud

1,538,497

0.93

0.89

0.04

0.66

0.04

136

0.17

0.16

4.00

2.38

437-SE

0


TOTAL INDICATED RESOURCE


11,999,177


1.48


1.40


0.07


1.32


0.04


137


0.28


0.17


5.79


3.44

Inferred – Current Lake

Upper Current

0

Current

0

Bridge

0

Beaver

1,735,331

0.80

0.75

0.05

0.79

0.02

146

0.20

0.18

3.72

2.21

Cloud

0

437-SE

4,671,629

0.64

0.61

0.07

1.01

0.01

114

0.34

0.13

3.28

1.95


TOTAL INFERRED RESOURCE


6,406,960


0.68


0.65


0.06


0.95


0.01


123


0.30


0.14


3.40


2.02


Notes: See section “Input Parameters for Resource Calculation” below.


Table 4: Current Lake Deposit – Contained Metal


Metal


Category


Area


Tonnes


Pt 
(Oz)


Pd
(Oz)


Au 
(Oz)


Ag
(Oz)


Rh 
(Oz)


Co
(Tonnes)


Cu
(Tonnes)


Ni
(Tonnes)


PtEq 
(Oz)


PdEq
 (Oz)

Indicated – Current Lake

Upper Current

1,089,212

56,185

52,487

2,692

60,154

2,342

161

3,800

2,150

227,801

135,523

Current

1,534,911

103,563

96,875

5,220

111,114

2,677

218

6,328

3,259

393,310

233,986

Bridge

3,355,050

185,255

179,929

8,702

160,257

5,079

436

11,851

5,832

720,020

428,351

Beaver

4,481,507

177,932

164,879

7,292

144,294

4,842

625

9,168

7,343

694,657

413,262

Cloud

1,538,497

46,241

44,010

2,216

32,615

2,058

209

2,604

2,385

197,787

117,667

437-SE

0


TOTAL INDICATED RESOURCE


11,999,177


569,176


538,181


26,121


508,434


16,998


1,649


33,751


20,969


2,233,575


1,328,789

Inferred – Current Lake

Upper Current

0

Current

0

Bridge

0

Beaver

1,735,331

44,527

41,708

2,718

44,020

1,031

253

3,446

3,203

207,495

123,442

Cloud

0

437-SE

4,671,629

95,873

91,625

10,170

151,464

806

533

15,709

5,910

493,125

293,368


TOTAL INFERRED RESOURCE


6,406,960


140,400


133,333


12,888


195,484


1,836


785


19,155


9,113


700,621


416,810


Notes: See section “Input Parameters for Resource Calculation” below.


Table 5: Escape Lake Deposit – Grade Summary


Grade


Category


Area


Tonnes


Pt
(g/t)


Pd
(g/t)


Au
(g/t)


Ag
(g/t)


Rh
(g/t)


Co
(g/t)


Cu
(%)


Ni
(%)


PtEq
(g/t)


PdEq
(g/t)

Indicated – Escape Lake

Steepledge North

135,650

0.71

0.81

0.06

1.28

0.01

157

0.28

0.18

3.87

2.30

Steepledge South

45,180

0.87

1.02

0.05

1.14

0.00

141

0.28

0.17

4.25

2.53

Escape South Perimeter

1,754,080

0.48

0.58

0.08

1.45

0.03

176

0.37

0.21

3.78

2.26

Escape South High-Grade Zone

2,351,310

1.27

1.65

0.16

3.29

0.08

238

0.66

0.34

8.11

4.82


TOTAL INDICATED RESOURCE


4,286,220


0.92


1.18


0.12


2.45


0.06


208.95


0.52


0.28


6.16


3.67

Inferred – Escape Lake

Steepledge North

148,609

0.44

0.52

0.05

0.53

0.00

150

0.26

0.21

3.14

1.87

Steepledge South

2,287,589

0.74

0.84

0.07

1.15

0.00

173

0.32

0.16

3.96

2.36

Escape South Perimeter

915,422

0.43

0.53

0.08

1.13

0.00

173

0.35

0.19

3.35

1.99

Escape South High-Grade Zone

93,559

0.43

0.34

0.09

1.45

0.01

191

0.38

0.20

3.29

1.96


TOTAL INFERRED RESOURCE


3,445,179


0.64


0.73


0.07


1.13


0.00


173


0.33


0.18


3.75


2.23


Notes: See section “Input Parameters for Resource Calculation” below.


Table 6: Escape Lake Deposit – Contained Metal


Metal


Category


Area


Tonnes


Pt
(Oz)


Pd
(Oz)


Au
(Oz)


Ag
(Oz)


Rh
(Oz)


Co
(Tonnes)


Cu
(Tonnes)


Ni
(Tonnes)


PtEq
(Oz)


PdEq
(Oz)

Indicated – Escape Lake

Steepledge North

135,650

3,087

3,545

266

5,577

43

21

383

238

16,897

10,053

Steepledge South

45,180

1,258

1,485

79

1,653

0

6

125

76

6,175

3,673

Escape South Perimeter

1,754,080

27,083

32,687

4,689

81,633

1,970

308

6,458

3,617

213,401

127,264

Escape South High-Grade Zone

2,351,310

95,662

124,619

11,894

249,083

5,996

560

15,424

8,085

613,007

364,380


TOTAL INDICATED RESOURCE


4,286,220


127,090


162,337


16,928


337,946


8,009


896


22,390


12,016


849,481


505,369

Inferred – Escape Lake

Steepledge North

148,609

2,119

2,462

255

2,508

0

22

394

309

14,985

8,915

Steepledge South

2,287,589

54,498

61,920

4,869

84,680

0

396

7,321

3,771

291,351

173,329

Escape South Perimeter

915,422

12,884

15,314

2,353

33,246

42

158

3,226

1,775

98,690

58,709

Escape South High-Grade Zone

93,559

1,019

1,293

276

4,375

29

18

353

190

9,905

5,896


TOTAL INFERRED RESOURCE


3,445,179


70,520


80,989


7,754


124,809


71


595


11,293


6,046


414,932


246,849


Notes: See section “Input Parameters for Resource Calculation” below.


2021 Exploration Update

A 2021 drill program on the initial resource at the Escape Lake Deposit will commence immediately with two drills, expanding the Escape Lake South high-grade zone area, upgrading Inferred material and filling in the gaps along the 3 km long conduit where geological potential for resource growth exists.

A third drill, commencing in Q2, 2021 will mobilize to the Current Lake Deposit area and upgrade Inferred material in the Beaver Lake Zone. Drilling will also test certain geophysical anomalies identified in last year’s work in the Feeder Zone area underlain by the Escape Lake Fault at the southern base of the Current Lake intrusion. The target in this area is the source of certain narrow, high grade massive sulphide lenses, found injected further up in the Current Lake conduit.


Social Engagement

Clean Air Metals and its wholly-owned subsidiary Panoramic PGMs (Canada) Limited acknowledge that the Escape Lake Property and the Current Lake Property, which collectively make up the Thunder Bay North Project, are on the traditional territories of the Fort William First Nation, Red Rock Indian Band and Biinjitiwabik Zaaging Anishinabek. The parties have entered into a Memorandum of Agreement as Cooperating Participants and are committed to ongoing updates and dialogue around the Thunder Bay North Project.


Input Parameters for Resource Calculation

Mining Cutoff Grade

The cutoff value used for the mineral resource is US$77/tonne (CA$101/tonne) insitu contained value, 1.58g/tonne Palladium Equivalent (PdEq) (US$77 / (US$1,516.82/31.10305)) or 2.65g/tonne Platinum Equivalent (US$77 / (US$902.38/31.10305)). The cutoff value is calculated based on estimations as follows: direct mining operating cost, onsite milling operating cost, tailings management facility operating cost, indirect operating cost, general and administration (G&A) cost, onsite milling metal recoveries, offsite smelting metal recoveries, and smelter metal payable percentages. A total estimated operating cost of CA$66.91/tonne of mill feed is comprised of;

  • Direct mining operating cost for underground mining of CA$35.88/tonne mill feed, consisting of the weighted average; 75% longhole open stope mining CA$30.45/tonne mill feed and 25% drift and fill mining CA$52.19/tonne mill feed,
  • Onsite milling and tailings management facility operating cost of CA$18.00/tonne mill feed,
  • Total indirect operating cost and G&A cost of CA$13.03/tonne mill feed.

Onsite estimated mill metal recoveries, offsite estimated smelting metal recoveries and estimated smelter payable percentages used for mineral resource cutoff grade calculations are summarized in Table 7. For resource cutoff calculation purposes, a mining recovery of 100.0% and 0.0% mining dilution were applied. The applicable metal prices are summarized in Table 8.


Table 7:


Contained Metals Parameters of Mineral Resource Cutoff Grade Calculations


Parameter


Pd


Pt


Ag


Au


Cu


Ni


Co


Rh

Onsite Mill Metal Recoveries

75.00%

75.00%

50.00%

50.00%

90.00%

90.00%

90.00%

75.00%

Offsite Smelting Metal Recoveries

85.00%

85.00%

85.00%

85.00%

85.00%

90.00%

50.00%

85.00%

Smelter Payable Percentages

98.00%

98.00%

85.00%

97.00%

100.00%

100.00%

100.00%

98.00%


Note: Values taken from Panoramic Resources “AMEC Technical Report dated 6 October 2010”.

Geological Domaining

Nordmin examined and modelled the mineralization within the Current Lake and Escape Lake deposits for the purpose of grade concentration and isolation of composites, while including lithological, geochemical, and structural correlations between rock types that are influencing the mineralization at each respective deposit.

Domain wireframes were modelled for seven grade elements, including combined Platinum (“Pt”) and Palladium (“Pd”), Gold (“Au”), Silver (“Ag”), Copper (“Cu”), Nickel (“Ni”), Cobalt (“Co”), and Rhodium (“Rh”).  Each domain was built using geology, mineralization, and grade bin for a combination of Background grade (“BG”), Low Grade (“LG”), Medium Grade (“MG”), and High Grade (“HG”).  Background grades were isolated through applying the overall conduit wireframe.  The criteria include:


Current Lake Deposit

  1. Platinum and Palladium: Platinum and Palladium grades were summed and the resulting total used to model with the following criteria: BG Pt+Pt < 2 g/t, LG Pt+Pt 2 g/t to 6 g/t, MG Pt+Pd 6 g/t to 12 g/t, HG Pt+Pd > 12 g/t
  2. Gold:  BG Au < 0.25 g/t, HG Au > 0.25 g/t
  3. Silver: BG Ag < 5 g/t, HG Ag > 5 g/t
  4. Copper: BG: < 1% Cu, LG 1% to 2% Cu, MG 2% to 4% Cu, HG > 4% Cu
  5. Nickel BG < 0.25% Ni, LG 0.25% to 0.5% Ni, MG 0.5% to 1% Ni, HG > 1% Ni
  6. Cobalt: BG Co < 250 g/t, LG Co 250 g/t to 500 g/t, HG Co > 500 g/t
  7. Rhodium: BG Rh < 0.25 g/t, LG Rh 0.25 g/t to 0.5 g/t, MG Rh 0.5 to 1.0 g/t, HG Rh > 1.0 g/t


Escape Lake Deposit

  1. Platinum and Palladium: Platinum and Palladium grades were summed and the resulting total used to model with the following criteria: BG Pt+Pt < 2 g/t, LG Pt+Pt 2 to 6 g/t, MG Pt+Pd 6 to 12 g/t, HG Pt+Pd > 12 g/t
  2. Gold:  BG Au < 0.25 g/t, HG Au > 0.25 g/t
  3. Silver: BG Ag < 2.5 g/t, LG Ag 2.5 g/t to 5 g/t, HG Ag > 5 g/t
  4. Copper: BG: < 1% Cu, LG 1% to 2% Cu, HG > 2% Cu
  5. Nickel BG < 0.25% Ni, LG 0.25% to 0.5% Ni, MG 0.5% to 1% Ni, HG > 1% Ni
  6. Cobalt: BG Co < 250 g/t, LG Co 250 g/t to 500 g/t, HG Co > 500 g/t
  7. Rhodium: BG Rh < 0.25 g/t, LG Rh 0.25 g/t to 0.5 g/t, MG Rh 0.5 g/t to 1.0 g/t, HG Rh > 1.0 g/t

Wireframes were initially created on 10 m to 20 m plan sections and adjusted on vertical section views to edit and smooth each wireframe where required. When not cut off by drilling, the wireframes terminate at the contact of the conduit or due to lack of drilling, whichever was most appropriate. No wireframe overlapping exists within a given domain, but all domains are independent of each other.

The use of explicit modelling allows for mineralization in context with the deposit geology and associated geochemistry to be considered. It is Nordmin’s opinion that the explicit modelling approach minimizes risks compared to using implicit modelling for each deposit.

Compositing

Compositing of samples is a technique used to give each sample a relatively equal length to reduce the potential for bias due to uneven sample lengths; it prevents the potential loss of sample data and reduces the potential for grade bias due to the possible creation of short and potentially high-grade composites that are generally formed along the zone contacts when using a fixed length.

The raw sample data was found to have a relatively narrow range of sample lengths. Samples captured within all zones were composited to 1.0 m regular intervals based on the observed modal distribution of sample lengths, which supports a 5.0 m x 5.0 m x 5.0 m block model (with sub-blocking). An option to use a slightly variable composite length was chosen to allow for backstitching shorter composites that are located along the edges of the composited interval. All composite samples were generated within each mineral lens with no overlaps along boundaries. The composite samples were validated statistically to ensure there was no loss of data or change to the mean grade of each sample population.

Block Model Resource Estimation

A “soft boundary” was used for the application of composites for all mineralized domains except for the background domains, as follows:

  • Background Grade: Selected composites include only background domain composites.
  • Low Grade: Selected composites included background and low-grade domain composites.
  • Medium Grade (where applicable): Selected composites included medium and low-grade domain composites.
  • High Grade (where applicable): Selected composites included high grade and medium grade domain composites.

A series of upfront test modelling was completed to define an estimation methodology to meet the following criteria:

  • Representative of the deposit geology and structural models.
  • Accounts for the variability of grade, orientation, and continuity of mineralization.
  • Controls the smoothing (grade spreading) of grades and the influence of outliers.
  • Accounts for most of the mineralization.
  • Is robust and repeatable within the mineral domains.
  • Supports multiple domains.

Multiple test scenarios were evaluated to determine the optimum processes and parameters to use to achieve the stated criteria. Each scenario was based on Natural Neighbour (NN), Inverse Distance Squared (ID2), Inverse Distance Cubed (ID3), and Ordinary Kriging (OK) spatial interpolation and weighted averaging methods.

All test scenarios were evaluated based on global statistical comparisons, visual comparisons of composite samples versus block grades, and the assessment of overall smoothing. Based on results of the testing, it was determined that the final resource estimation methodology would constrain the mineralization by using hard wireframe boundaries to control the spread of high to grade and low to grade mineralization. OK was selected as the best representative interpolation method.

Equivalency

Equivalency formulas were calculated and used for reporting purposes.  The derivation of the equivalency formulas is based on accepted industry practices.  All equivalencies are reported as in-situ grades and are calculated using the trailing average commodity price deck referenced in Table 8.

Platinum equivalency (“Pt Eq”) and Palladium Equivalency (“Pd Eq”) was calculated for each deposit through the following formulas, using components from platinum (“Pt”), palladium (“Pd”), gold (“Au”), silver (“Ag”), copper (“Cu”), nickel (“Ni”), cobalt (“Co”), and rhodium (“Rh”):

Notes:

  • All percentage grades referenced in the formulas for Cu and Ni are numeral percentage rather than decimal percentages (i.e., 2% is 2.0, not 0.02).
  • 0.06857 is used for troy ounce and pound conversion.
  • 2204 is used for tonne and pound conversion.
  • 10,000 is used to convert from numerical percentage to grams.

Additional

  • The Independent and Qualified Person responsible for the Mineral Resource Estimate is Glen Kuntz, P.Geo. of Nordmin Engineering Ltd., Thunder Bay, Ontario, and the effective date of the estimate is January 18, 2021.
  • CIM Definition Standards on Mineral Resources and Reserves were used for the Thunder Bay North Project mineral resource estimate.
  • 3-year trailing average prices were used for all calculations with the exception of cobalt which used a 2-year trailing average price as itemized in Table 8.
  • Resource excludes all material immediately below Current Lake, above a minimum crown pillar thickness of 20m which is assumed to be not recoverable by underground methods.
  • Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The estimate of mineral resources may be materially affected by environmental, permitting, legal, marketing, or other relevant issues.
  • Minor variations may occur during the addition of rounded numbers.
  • Calculations used metric units (meters (m), tonnes (t) and grams/tonne (g/t).


Table 8: Commodity Prices Used in Resource Calculation


Commodity


Units


Assumption
(USD$)

Palladium

per oz

$ 1,516.82

Platinum

per oz

$ 902.38

Silver

per oz

$ 17.35

Gold

per oz

$ 1,469.60

Copper

per lbs

$ 2.87

Nickel

per lbs

$ 6.15

Cobalt

per tonne

$ 34,839.16

Rhodium

per oz

$ 4,910.67


Note: 3-year trailing average except Cobalt is 2-year trailing average.

Qualified Persons

The Mineral Resource estimate was independently prepared under the supervision of Mr. Glen Kuntz, P.Geo. (Ontario) of Nordmin Engineering Ltd., a “Qualified Person” under National Instrument 43-101 Standards of Disclosure for Mineral Projects. Verification included a site visit to inspect drilling, logging, density measurement procedures and sampling procedures, and a review of the control sample results used to assess laboratory assay quality. In addition, a random selection of the drill hole database results was compared with original records.

About Clean Air Metals Inc.

Clean Air Metals’ flagship asset is the Thunder Bay North Project, a platinum, palladium, copper, nickel project located near the City of Thunder Bay, Ontario and the Lac des Iles Mine owned by Impala Platinum Holdings. The Clean Air Metals project hosts the Current Lake Deposit and magma conduit and the Company is actively exploring the Escape Lake Deposit, a twin structure to the Current Lake Deposit. Executive Chairman Jim Gallagher, P.Eng. and CEO Abraham Drost, P.Geo. lead an experienced team of geologists and engineers who are using the Norilsk magma conduit stratigraphic and mineral deposit model to guide ongoing exploration and development studies. As the former CEO of North American Palladium Ltd. which owned the Lac des Iles Mine prior to the sale to Impala Platinum in December, 2019, Jim Gallagher and team are credited with the mine turnaround and creation of significant value for shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS

“Abraham Drost”
Abraham Drost, Chief Executive Officer of Clean Air Metals Inc.

For further information, please contact:

Abraham Drost, Chief Executive Officer of Clean Air Metals Inc.
Phone: 807-252-7800
Email: [email protected]
Website: www.cleanairmetals.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note

The information contained herein contains “forward-looking statements” within the meaning of applicable securities legislation, including statements regarding the potential of the Thunder Bay North Project and the Escape Lake and Current Lake deposits and timing of technical studies and mineral resource estimates. Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. Any statements that express predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings; risks related to environmental regulation and liability; the potential for delays in exploration or development activities or the completion of feasibility studies; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; results of prefeasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company’s expectations; risks related to commodity price fluctuations; and other risks and uncertainties related to the Company’s prospects, properties and business detailed elsewhere in the Company’s disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty to forward-looking statements. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances, except in accordance with applicable securities laws. Actual events or results could differ materially from the Company’s expectations or projection.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/clean-air-metals-announces-a-mineral-resource-for-the-thunder-bay-north-project-including-a-total-indicated-resource-of-16-285-396-tonnes-at-an-average-grade-of-3-5-gt-pdeq-containing-1-834-158-ounces-pdeq-and-a-total-inferred-re-301211547.html

SOURCE Clean Air Metals Inc.

WiMi Wins 2020 Award for Leadership in Computer Vision Holographic Cloud Services

PR Newswire

BEIJING, Jan. 20, 2021 /PRNewswire/ — WiMi Hologram Cloud Inc. (Nasdaq: WIMI) (“WiMi” or the “Company”), a leading Hologram Augmented Reality (“AR”) Technology provider in China, today announced that it has won the award from CCIDnet for leading company of 2020 in computer vision holographic cloud services as a result of its outstanding performance in technological innovation and widespread public approval.

CCIDnet is managed by CCID group, which is a subsidiary of China’s Ministry of Industry and Information Technology. As an influential and innovative online media platform, CCIDnet covers timely industry news and events. CCIDnet also organizes the Innovative Influence Annual Conference, which occurs annually and has been one of the most influential annual events in the science and technology industry since it was initially launched in 2010. In 2020, the Innovative Influence Annual Conference and Top 100 Achievements event (the “Event”) focused on the theme of “Digital New Economy, Wise New Society.” During the Event, organizers summarized the innovation achievements of 2020 and the coming technological trends of 2021, shared 2020’s most successful technologies, products, solutions, and use cases, and highlighted outstanding achievements in 2020 across various fields via an online cloud presentation and offline gallery exhibition.

Empowered by its new holographic technology utilizing optical projections, WiMi provides one-stop services and holographic AR technologies to its customers, including the synthesis and presentation of holographic AI vision, interactive holographic software development, holographic AR advertisements, holographic AR SDK payments, holographic 5G communications software development, holographic AR automotive software, and holographic facial recognition. The commercial application of these services and technologies covers advertising display systems, commercial publishing systems, performing arts systems, light field cinemas, home entertainment, and more. To date, WiMi has developed the world’s leading 3D computer vision and SAAS platform technologies. WiMi has also made significant progress in its ability to transform ordinary images into holographic content through its use of proprietary AI algorithms. Many fields, including education, entertainment, advertising, and communications, regularly utilize such holographic content to create highly interactive and engaging experiences for audiences. Looking ahead, as holographic 5G communications, mobile broadband, and Internet of Things technology continue to develop, it is also expected that the holographic cloud industry will experience significant growth in turn.

About WIMI Hologram Cloud Inc.

WiMi Hologram Cloud, Inc.(NASDAQ: WIMI), whose commercial operations began in 2015, is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, holographic pulse laser, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation and others. Its services and holographic AR technologies include holographic AR automotive application, holographic laser automotive application, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, automobile holographic communication and other holographic AR technologies. For more information, please visit http://ir.wimiar.com.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release, as well as the Company’s strategic and operational plans, contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”) on Forms 20−F and 6−K, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition and results of operations; the expected growth of the AR holographic industry; and the Company’s expectations regarding demand for and market acceptance of its products and services. Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable laws. 

Contacts

WIMI Hologram Cloud Inc.
Email: [email protected]

ICR, LLC
Sharon Zhou
Tel: +1 (646) 975-9495
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/wimi-wins-2020-award-for-leadership-in-computer-vision-holographic-cloud-services-301211579.html

SOURCE WiMi Hologram Cloud Inc.

Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference

PR Newswire

NEW YORK, Jan. 20, 2021 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium”) today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20th to 21st.  During the event, Sandesh Seth, Actinium’s Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer will participate in a fireside chat discussion moderated by B. Riley analyst Justin Walsh.


Fireside Chat Details

Event:     

B. Riley Oncology Investor Conference

Participants:

Sandesh Seth, Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer

Date:

Thursday, January 21st

Time:

3:30 p.m. ET

In addition, members of the executive team will be available for one-on-one meetings with conference attendees.  Those interested in scheduling a meeting may do so by contacting their B. Riley representative or the Company at [email protected].  

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.  Actinium’s lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.  With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.  Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.  The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.  More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy and Phase 1/2 anti-HIV stem cell gene therapy with UC Davis.  In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.  Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.  Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.  This is where our intellectual property portfolio of over 130 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes.  Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Contacts:

Investors:
Clayton Robertson
Actinium Pharmaceuticals, Inc.
[email protected]

Hans Vitzthum

LifeSci Advisors, LLC
[email protected]
(617) 430-7578

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference-301211474.html

SOURCE Actinium Pharmaceuticals, Inc.

Main Street Announces Fourth Quarter 2020 Private Loan Portfolio Activity

PR Newswire

HOUSTON, Jan. 20, 2021 /PRNewswire/ — Main Street Capital Corporation (NYSE: MAIN) (“Main Street”) is pleased to announce the following recent activity in its private loan portfolio. During the fourth quarter of 2020, Main Street originated approximately $80.5 million in new private loan commitments across four (4) new borrowers and funded total new investments across its private loan portfolio with a cost basis totaling approximately $98.5 million.

The following represent notable new and incremental private loan commitments during the fourth quarter of 2020:

  • $35.0 million in a first lien senior secured loan and $2.5 million in a first lien senior secured revolver to an executive search placement firm focused on the healthcare and life sciences industry;
  • $15.5 million in a first lien senior secured loan and $4.7 million in a senior secured delayed draw loan to an operator of futures trading platforms;
  • $11.4 million in a first lien senior secured loan, $5.7 million in a first lien senior secured delayed draw loan and $2.9 million in a first lien senior secured revolver to a manufacturer and distributor of residential and commercial fencing;
  • $12.0 million in a first lien senior secured loan and $1.0 million in a first lien senior secured revolver to a subcontractor of interior acoustical walls and ceilings;
  • $10.0 million in a first lien senior secured loan to a provider of physical and virtual application delivery controllers and an operator of a global network intelligence company; and
  • $10.0 million in a first lien senior secured loan to a manufacturer and distributor of charitable gaming supplies to the global social and charitable gaming market.

As of December 31, 2020, Main Street’s private loan portfolio included total investments at cost of approximately $769.0 million across 63 unique borrowers. The private loan portfolio, as a percentage of cost, included 90% invested in first lien debt investments, 3% invested in second lien debt investments, and 7% invested in equity investments or other securities. 

ABOUT MAIN STREET CAPITAL CORPORATION
Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides long-term debt and equity capital to lower middle market companies and debt capital to middle market companies.  Main Street’s portfolio investments are typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors.  Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides “one stop” financing alternatives within its lower middle market portfolio.  Main Street’s lower middle market companies generally have annual revenues between $10 million and $150 million.  Main Street’s middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies.

Main Street, through its wholly owned portfolio company MSC Adviser I, LLC (“MSC Adviser”), also maintains an asset management business through which it manages investments for third parties.  MSC Adviser is registered as an investment adviser under the Investment Advisers Act of 1940.   

Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, CEO, [email protected]
Brent D. Smith, CFO, [email protected] 
713-350-6000


Dennard Lascar Investor Relations

Ken Dennard | [email protected]
Zach Vaughan | [email protected]
713-529-6600

Cision View original content:http://www.prnewswire.com/news-releases/main-street-announces-fourth-quarter-2020-private-loan-portfolio-activity-301211381.html

SOURCE Main Street Capital Corporation

Resolute Prices $300 Million Senior Unsecured Notes Offering

PR Newswire

US $

MONTRÉAL, Jan. 20, 2021 /PRNewswire/ – Resolute Forest Products Inc. (NYSE: RFP) (TSX: RFP) today announced that it priced the private offering of $300 million aggregate principal amount of its senior unsecured notes due 2026 (the “2026 Notes“) at 4.875% and 100% of par value. The 2026 Notes will be unsecured and will be guaranteed by all of Resolute’s material wholly owned U.S. subsidiaries. Resolute expects to use the net proceeds from the offering of the 2026 Notes, together with cash on hand and/or borrowings under the Company’s senior secured asset-based revolving credit facility and/or its senior secured credit facility, to redeem all of its outstanding 5.875% senior notes due 2023 (the “2023 Notes“), of which $375 million aggregate principal amount is currently outstanding. The Company today instructed the 2023 Notes indenture trustee to give a notice of redemption to redeem all outstanding 2023 Notes on February 18, 2021 at a price of 100.000% of the aggregate principal amount thereof, plus interest to, but not including the redemption date and depositing the redemption price for the 2023 Notes with the 2023 Notes indenture trustee. The redemption is conditional on, among other things, the Company’s successful consummation of the sale of the 2026 Notes. The 2026 Notes offering is expected to close on February 2, 2021, subject to customary closing conditions.

The 2026 Notes are being offered and sold to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, and to non-U.S. persons in reliance on Regulation S under the Securities Act. The 2026 Notes have not been and will not be registered under the Securities Act or any state securities laws. Therefore, the 2026 Notes may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offering, solicitation or sale would be unlawful. This press release is not a notice of redemption for the 2023 Notes. This press release is issued pursuant to and in accordance with Rule 135c under the Securities Act.

Cautionary Statements Regarding Forward-Looking Information

Statements in this press release that are not reported financial results or other historical information of Resolute are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They include, for example, statements relating to the impact of the novel coronavirus (or, “COVID-19”) pandemic and resulting economic conditions on Resolute’s business, results of operations and market price of its securities, and to its: efforts and initiatives to reduce costs, increase revenues, and improve profitability; business and operating outlook; future pension obligations; assessment of market conditions; growth strategies and prospects, and the growth potential of Resolute and the industry in which it operates; liquidity; future cash flows, including as a result of the changes to Resolute’s pension funding obligations; estimated capital expenditures; and strategies for achieving its goals generally. Forward-looking statements may be identified by the use of forward-looking terminology such as the words “should,” “would,” “could,” “will,” “may,” “expect,” “believe,” “see,” “anticipate,” “continue,” “attempt,” “focus on,” “improve,” “challenge,” “positioned,” “maintain,” “strive,” “trend,” “strategy,” “seek,” “evolve,” “vision,” “commit,” “develop,” “project,” “progress,” “build,” “pursue,” “plan,” “grow” and other terms with similar meaning indicating possible future events or potential impact on Resolute’s business or its shareholders.

The reader is cautioned not to place undue reliance on these forward-looking statements, which are not guarantees of future performance. These statements are based on management’s current assumptions, beliefs, and expectations, all of which involve a number of business risks and uncertainties that could cause actual results to differ materially. The potential risks and uncertainties that could cause Resolute’s actual future financial condition, results of operations and performance to differ materially from those expressed or implied in this press release include, but are not limited to, the impact of: the COVID-19 pandemic and resulting economic conditions; developments in non-print media, and the effectiveness of Resolute’s responses to these developments; intense competition in the forest products industry; any inability to offer products certified to globally recognized forestry management and chain of custody standards; any inability to successfully implement Resolute’s strategies to increase its earnings power; the possible failure to successfully integrate acquired businesses with Resolute or to realize the anticipated benefits of acquisitions, such as its entry into wood manufacturing in the U.S., and tissue production and sales, or divestitures or other strategic transactions or projects, including loss of synergies following business divestitures; uncertainty or changes in political or economic conditions in the U.S., Canada or other countries in which Resolute sells its products, including the effects of pandemics; global economic conditions; the highly cyclical nature of the forest products industry; any difficulties in obtaining timber or wood fiber at favorable prices, or at all; changes in the cost of purchased energy and other raw materials; physical and financial risks associated with global, regional, and local weather conditions, and climate change; any disruption in operations or increased labor costs due to labor disputes or occupational health and safety issues; difficulties in Resolute’s employee relations or in employee attraction or retention; disruptions to Resolute’s supply chain, operations, or the delivery of its products, including due to public health epidemics; disruptions to Resolute’s information technology systems including cybersecurity incidents; risks related to the operation and transition of legacy system applications; negative publicity, even if unjustified; currency fluctuations; any increase in the level of required contributions to Resolute’s pension plans, including as a result of any increase in the amount by which they are underfunded; Resolute’s ability to maintain adequate capital resources to provide for all of its substantial capital requirements; the terms of Resolute’s outstanding indebtedness, which could restrict its current and future operations; changes relating to the London Interbank Offered Rate, which could impact Resolute’s borrowings under its credit facilities; losses that are not covered by insurance; any shutdown of machines or facilities, restructuring of operations or sale of assets resulting in any additional closure costs and long-lived asset impairment or accelerated depreciation charges; any need to record additional valuation allowances against Resolute’s recorded deferred income tax assets; Resolute’s exports from one country to another country becoming or remaining subject to duties, cash deposit requirements, border taxes, quotas, or other trade remedies or restrictions; countervailing and anti-dumping duties on imports to the U.S. of the vast majority of Resolute’s softwood lumber products produced at its Canadian sawmills; any failure to comply with laws or regulations generally; any additional environmental or health and safety liabilities; any violation of trade laws, export controls, or other laws relating to Resolute’s international sales and operations; adverse outcomes of legal proceedings, claims and governmental inquiries, investigations, and other disputes in which Resolute is involved; the actions of holders of a significant percentage of Resolute’s common stock; and the potential risks and uncertainties set forth under Part I, Item 1A, “Risk Factors,” of Resolute’s annual report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission (or, the “SEC“) on March 2, 2020 which have been heightened by the COVID-19 pandemic, including related governmental responses and economic impacts, market disruptions and changes in consumer habits, and which should be read in conjunction with the COVID-19 pandemic risk factor update further set forth in Part II, Item 1A, “Risk Factors,” in Resolute’s quarterly report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 9, 2020.

All forward-looking statements are expressly qualified by the cautionary statements contained or referred above and in Resolute’s other filings with the SEC and the Canadian securities regulatory authorities. Resolute disclaims any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

About Resolute Forest Products

Resolute Forest Products is a global leader in the forest products industry with a diverse range of products, including market pulp, tissue, wood products and papers, which are marketed in close to 70 countries. The company owns or operates some 40 facilities, as well as power generation assets, in the United States and Canada. Resolute Forest Products has third-party certified 100% of its managed woodlands to internationally recognized sustainable forest management standards. The shares of Resolute Forest Products trade under the stock symbol RFP on both the New York Stock Exchange and the Toronto Stock Exchange.

Resolute has received regional, North American and global recognition for its leadership in corporate social responsibility and sustainable development, as well as for its business practices. 

Cision View original content:http://www.prnewswire.com/news-releases/resolute-prices-300-million-senior-unsecured-notes-offering-301211420.html

SOURCE Resolute Forest Products Inc.

Bullfrog Confirms Date of Name Change and Share Consolidation; Further Strengthens Its Board

PR Newswire

VANCOUVER, BC, Jan. 20, 2021 /PRNewswire/ – Bullfrog Gold Corp. (OTCQB: BFG) (CSE: BFG) (FSE: 11B) (“Bullfrog” or the “Company”) today confirms that its shares will begin trading under the name “Augusta Gold Corp.,” on a post-consolidated basis of one (1) new share for every six (6) old shares at open of market on January 25, 2021 (the trading day immediately preceding the effective date). The Company’s trading symbol on the Canadian Securities Exchange will be changed to “G”.

Mr. Len Boggio has also been appointed to the Company’s Board of Directors effective immediately. 

Maryse Belanger, President and CEO commented: “I am pleased that Len has agreed to join our Board, he is a very seasoned finance professional with extensive experience at the board level.  His experience in financial reporting and auditing, public finance offerings and mergers and acquisitions will be beneficial to all shareholders as we advance the Bullfrog Gold project in Nevada.”  

Mr. Boggio was formerly a partner of PricewaterhouseCoopers LLP (PwC) where he served for more than 30 years until his retirement in May 2012. During that time, he was Leader of the B.C. Mining Group of PwC, a senior member of PwC’s Global Mining Industry Practice and an auditor of Canadian, U.S. U.K. and other internationally-listed mineral resource and energy clients. Mr. Boggio is a Fellow of the Chartered Professional Accountants of Canada (FCPA, FCA) and has served as president of the British Columbia Institute of Chartered Accountants and chairman of the Canadian Institute of Chartered Accountants.

Additional information on the share consolidation can be found in the Company’s news release dated January 7, 2021 and in the definitive information statement filed by the Company with the U.S. Securities and Exchange Commission and on SEDAR. Stockholders who have existing stock certificates will receive written instructions by mail from the Company’s transfer agent. Stockholders who hold their shares in brokerage accounts are not required to take any action to affect the exchange of their shares.

About Bullfrog Gold Corp.

Bullfrog Gold is a rapidly growing exploration and development company focused on building a long-term business that delivers stakeholder value through developing the Bullfrog Gold Project and pursing accretive M&A opportunities.  The Bullfrog Gold Project is located in the prolific Bullfrog district approximately 120 miles north-west of Las Vegas, Nevada and 4 miles west of Beatty, Nevada. The Company controls 6,750 acres of mineral rights including the Bullfrog and Montgomery-Shoshone deposits and has further identified significant additional mineralization around the existing pits and defined several exploration targets that could further enhance the Project.  The Company is led by a management team and board of directors with a proven track record of success in financing and developing mining assets and delivering shareholder value. For more information please visit www.bullfroggold.com.

Forward Looking Statements

Certain statements and information contained in this new release constitute “forward-looking statements”, and “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking statements”). These statements include the date that the Company’s consolidation, name change and symbol change will become effective; the date that the Company’s common shares will begin trading on a post-consolidation under its new name and symbol; and that Mr. Boggio’s experience will be beneficial to all shareholders as we advance the Bullfrog Gold project in Nevada. Such forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this news release words such as “will” and similar expressions are intended to identify these forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements and/or information are reasonable, undue reliance should not be placed on forward-looking statements since the Company can give no assurance that such expectations will prove to be correct. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements, including the risks, uncertainties and other factors identified in the Company’s periodic filings with Canadian securities regulators. These forward-looking statements are based largely on current expectations and projections about future events and financial trends affecting the financial condition of our business. These forward-looking statements were derived using numerous assumptions. While the company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. 

Forward-looking statements are based on information available at the time those statements are made and/or management’s and/or its qualified persons’ good faith belief as of that time with respect to future events, and are subject to information currently available, they may prove to be incorrect. Forward-looking statements are based on information available at the time those statements are made and/or management’s and/or its qualified persons’ good faith belief as of that time with respect to future events, and are subject to known and unknown risks and uncertainties outlined in the Company’s corporate disclosure and other documents filed on

www.sec.gov

 and 

www.sedar.com

, that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Forward-looking statements speak only as of the date those statements are made. Except as required by applicable law, we assume no obligation to update or to publicly announce the results of any change to any forward-looking statement contained herein to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward- looking statements. If we update any one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. You should not place undue importance on forward-looking statements and should not rely upon these statements as of any other date. All forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bullfrog-confirms-date-of-name-change-and-share-consolidation-further-strengthens-its-board-301211421.html

SOURCE Bullfrog Gold Corp.

Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium

PR Newswire

Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens Scleral Lenses on Patients

LAVAL, QC, Jan. 20, 2021 /PRNewswire/ — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced that two poster presentations will feature data on the new Bausch + Lomb INFUSE silicone hydrogel (SiHy) daily disposable contact lenses during the virtual Global Specialty Lens Symposium (GSLS) Annual Meeting, which takes place Jan. 21-23, 2021. Bausch + Lomb also will offer attendees the opportunity to participate in a presentation about its Zenlens scleral lenses.

“The continued response from patients has been overwhelmingly positive since we launched this breakthrough new lens last year in the United States, Canada and other countries around the world.* In fact, in a survey among patients who tried Bausch + Lomb INFUSE lenses, 97% of patients agreed Bausch + Lomb INFUSE lenses provide crisp, clear vision throughout the day, and 94% of patients agreed Bausch + Lomb INFUSE helps keep contact lenses from feeling dry,”1 said Joseph C. Papa, chairman and CEO, Bausch Health. “We are proud to continue to support ongoing research on this unique lens to help eye care professionals understand its clinical benefits and relevance for patients.”

Bausch + Lomb INFUSE Poster Presentations
The Bausch + Lomb INFUSE poster presentations will be accessible to conference attendees via the GSLS website from Jan. 21-23, 2021.

The poster presentations are as follows:

  • Scheuer, Catherine et al. “Impact of a Novel Contact Lens on Maintaining the Native State of a Tear Film Protein”
    • An in vitro study to investigate the ability of a contact lens solution to stabilize the representative tear film protein lysozyme in its native state.
  • Steffen, Robert et al. “Evaluation of the Stability of Surface Water Characteristics of Contact Lenses Using Refractive Index Shifts after Wear of Daily Disposable Lenses”
    • A study to investigate surface water stability using refractive index shifts after insertion for four unique polymers, kalifilcon A, delefilcon A, verofilcon A and nesofilcon A.

Zenlens™ Event Presentation
On Jan. 22, 2021, from 5:15 to 5:45 p.m. ET, Bausch + Lomb will host a presentation featuring one of its prominent custom contact lenses, Zenlens scleral lenses, led by Jason Jedlicka O.D., FAAO, FSLS, FCLSA, associate professor and director of the Cornea and Contact Lens Service, Indiana University School of Optometry. During the event, “Using Technology for Fitting Success”, Dr. Jedlicka will discuss how technology can help create fitting efficiencies using the Zenlens lenses through the use of corneal topography, scleral topography and anterior segment optical coherence tomography.

About Bausch + Lomb INFUSE Contact Lenses
Bausch + Lomb INFUSE contact lenses are the only SiHy daily disposable with a next generation material infused with ProBalance Technology that work together to help maintain ocular surface homeostasis to help minimize symptoms of contact lens dryness and discomfort for exceptional clarity and comfort. The ProBalance Technology™ formula is infused into the lens material during the manufacturing process. These proprietary ingredients are released during lens wear. Bausch + Lomb INFUSE combines exceptional breathability for healthy lens wear with high moisture content and a low modulus. It also maintains 96% of its moisture for a full 16 hours. For more information on Bausch + Lomb INFUSE contact lenses, visit http://www.bauschinfuse.com/.

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

* Bausch + Lomb INFUSE silicone hydrogel daily disposable contact lenses are branded as BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses in Canada.

References

1. Results of an online survey with patients who completed an evaluation program for Bausch + Lomb INFUSE contact lenses and wore their trial lenses for ≥7 days (n=777). Survey results include patients who strongly agreed, agreed, or slightly agreed (on a 6-point agreement scale) with the surveyed statement, with a margin of error ±1.7%.

®/TM
 are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names are trademarks of the respective owners.
© 2021 Bausch & Lomb Incorporated or its affiliates.
MTB.0030.USA.21


Investor Contact:


Media Contact:

Arthur Shannon 

Lainie Keller



[email protected]
                                          


[email protected]

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)                                                  

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch–lomb-announces-scientific-data-on-bausch–lomb-infuse-silicone-hydrogel-daily-disposable-contact-lenses-to-be-presented-at-the-virtual-global-specialty-lens-symposium-301211447.html

SOURCE Bausch Health Companies Inc.

Biomica Announces Participation at the 5th Microbiome Movement Drug Development Europe Conference on January 28-29, 2021 (Virtual Conference)

PR Newswire

REHOVOT, Israel, Jan. 20, 2021 /PRNewswire/ — Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference.  The conference is being held on January 28-29, 2021, virtually.

Biomica Logo

Dr. Elran Haber, Biomica’s Chief Executive Officer, is scheduled to speak on the European Microbiome Leaders Panel during the morning opening plenary session on January 28 at 9:00 am CET.

The panel discussion will address current strategies to take microbiome-based therapeutics to market; the role of partnerships in future therapeutic strategies; what public institutions and regulators can do to support the microbiome sector; what tools can be utilized to reveal causation and molecular mechanisms of microbiome-based therapeutics; and where the industry is developing over the next five years.

Dr. Shiri Meshner, VP R&D of Biomica, will be presenting for the first time the positive and exciting results, as recently reported, from Biomica’s pre-clinical trials in its immune-oncology program in her presentation titled: “From Computational Predictions to Preclinical Performance”.

The presentation will be available after the conference.

To register as a participant of the conference see https://microbiome-europe.com/

About Biomica:

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders.

Biomica is a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN). For more information, please visit www.biomicamed.com.

About Evogene Ltd.:

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and advanced computational technologies. Today, this platform is utilized by the Company to discover and develop innovative products in the main following areas (via subsidiaries or divisions): ag-chemicals, ag-biologicals, seed traits, human microbiome-based therapeutics and medical cannabis. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in their collaborations with world-leading companies such as BASF, Bayer, Corteva, and ICL. For more information, please visit www.evogene.com.

Contact:

Rivka Neufeld/ Aviva Banczewski
Investor Relations and Public Relations Manager
E: [email protected]
T: +972-8-931-1900

US Investor Relations:

Joseph Green

Edison Group
E: [email protected]
T: +1 646-653-7030

Laine Yonker
Edison Group
E: [email protected]
T: +1 646-653-7035

Evogene Logo

Cision View original content:http://www.prnewswire.com/news-releases/biomica-announces-participation-at-the-5th-microbiome-movement-drug-development-europe-conference-on-january-28-29-2021-virtual-conference-301211580.html

SOURCE Biomica

First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study


               

First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study

Inivata’s InVisionFirst®-Lung is being used for ctDNA testing and monitoring of
patients treated with lorlatinib

Study
supported by a grant from Pfizer Inc.

Research Triangle Park, NC, USA and Cambridge, UK, 20 January 2021 – Inivata, a leader in liquid biopsy, today announces that the first patients have been tested using InVisionFirst®-Lung as part of the Phase II ALKALINE trial sponsored by the European Organisation for Research and Treatment of Cancer (EORTC). As part of the study Inivata’s InVisionFirst-Lung liquid biopsy will be used to test and monitor ALK positive non-small cell lung cancer (NSCLC) patients initiating treatment with lorlatinib, Pfizer Inc.’s third generation ALK inhibitor therapy.

The aim of this academic trial, announced in 2019 and being supported by Pfizer, is to examine the resistance to lorlatinib in ALK positive NSCLC patients. While in the past these patients were known to respond well to ALK inhibition therapies, such as lorlatinib, drug resistance in patients has been increasing. This trial is designed to provide insights for clinicians and researchers to better understand resistance mechanisms, and to analyze the correlation between ALK resistance mutational profile and response to lorlatinib. A total of 100 patients will be involved in two study designs run in parallel across 30 participating EORTC sites across Europe.

The Phase II study is a single arm, multicenter study. InVisionFirst-Lung will be used to provide data on ALK mutational profile following progression to second generation TKI’s, prior to lorlatinib treatment. This mutational profile will be correlated with lorlatinib treatment outcome after 12 months. In addition, each patient’s response to lorlatinib treatment at the point of disease progression will be monitored using ctDNA profiling for new ALK mutations or other resistance mechanisms. This study will help clinicians to understand which patient populations are more likely to benefit from lorlatinib treatment and may also inform further treatment strategies.

InVisionFirst-Lung is also being used to provide longitudinal assessment for the sub-study selection of patients through the detection of molecular resistance at the time of disease progression to second generation TKIs. This will inform on the time of emergence of ALK and other resistance mutations and the relevance of liquid biopsy monitoring for clinical outcomes.

Clive Morris, Chief Executive Officer of Inivata, commented: This is a positive step forward in our collaboration with the EORTC, as we work together to unlock insights which will help us improve patient treatment in cases of drug resistance, an increasing global health challenge. Inivata’s involvement in this study highlights the value of the InVision® platform in optimizing patient recruitment in trials and providing rapid and repeatable genomic insights to researchers, and more broadly supports the utilization of liquid biopsy technology in clinical settings.”

Laura Mezquita, MD PhD
, Department of Medical Oncology, Hospital Clinic, Barcelona, and co-PI of ALKALINE trial, commented: “It is of vital importance that clinicians gain a better understanding of the patterns of resistance to drug therapies in cancer treatment, where time is of the essence in ensuring the best outcomes for patients. We hope that this study will not only provide insights on how to adjust existing treatment regimens to make them more effective for patients, but could also assist in the development of combination treatments, which would prevent this build-up of resistance in the first place.”  

Professor Anne-Marie Dingemans, MD PhD, Professor of Pulmonology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam and Senior PI of ALKALINE trial, said: “UsingInivata’s InVisionFirst-Lung liquid biopsy in this trial will enable us to test and closely monitor patients throughout the course of the study with high confidence in the accuracy of the data. By learning which patients are more responsive to lorlatinib, we hope that the findings of this study will be able to help clinicians to make better informed decisions for their patients.”

About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available internationally and through NeoGenomics in the US. It offers competitive sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow Inivata on Twitter @Inivata.

About EORTC (European Organisation for Research and Treatment of Cancer)

European Organisation for Research and Treatment of Cancer conducts clinical research in cancer, defining new standards of practice for better treatment and care of cancer patients. EORTC network comprises more than 5300 multidisciplinary collaborators in more than 930 hospitals and institutions in 37 countries. For more information, visit www.eortc.org.

Media Contacts:

Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson
[email protected] +44 (0)20 3709 5700, +1 516 503 0271

Karen Chandler-Smith
[email protected] +44 (0)7900 430235



Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta

Press release

Synairgen plc

(‘Synairgen’ or the ‘Company’)

Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta




– Establishing proof of concept for home administration  

Southampton, UK – 20 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that recruitment of 120 COVID-19 patients into its Phase II trial evaluating inhaled formulation of interferon-beta-1a (SNG001) conducted in the home setting has now been completed. Results from the trial are expected in Q2 2021.

The COVID-19 Phase II Study (SG016)

Synairgen’s two-part, placebo-controlled trial evaluating SNG001 as a treatment for COVID-19 infection involved dosing of (i) 101 patients in the hospital setting, the positive results from which were published in The Lancet Respiratory Medicine in November 20201, and (ii) 120 ‘at risk’ patients in the home setting, recruitment for which completed yesterday.

Innovative Virtual Trial Design for Home-Based Study

The study targeted patients with a positive SARS-CoV-2 test result aged over 65, and those over the age of 50 with ‘high risk’ medical conditions. The trial was designed to make it easy and safe for trial participants and researchers to conduct the study; all ­supplies were delivered directly to the patient’s door by a courier, and all trial assessments were conducted remotely by study doctors and nurses via video call. The study has confirmed the feasibility of rapid roll-out of antiviral treatment in the context of a pandemic, where there is a need to limit the movement of people to minimise risks to patients, the public and healthcare providers.

The trial was conducted in collaboration with the NIHR Southampton Clinical Trials Unit and TranScrip Partners.

Richard Marsden, CEO of Synairgen, commented:
“We are pleased to have completed recruitment of 120 ‘at risk’ patients into this innovative placebo-controlled trial whereby all trial ‘visits’ were conducted by video call. The trial is both a test of the drug, and a test of how technology can be utilised to deliver and manage the administration of an inhaled broad-spectrum antiviral to vulnerable patients in the context of a pandemic, reducing the need to transport infected patients, and eliminating virus exposure to healthcare workers. We believe this methodology and treatments such as SNG001 could be invaluable alongside vaccines, now and in the future, to fight highly pathogenic viruses such as SARS-CoV-2. We are extremely grateful to the team of healthcare workers, pharmacists and logistics providers who have worked tirelessly to deliver this trial which is a further example of great British science, attracting interest from academia and governments around the world.”

Professor Nick Francis, Professor of General Practice at the University of Southampton, commented: 
“We are delighted to announce completion of recruitment into the SG016 Home trial. This is a remarkable trial evaluating a novel therapeutic delivered in the home setting to people with COVID-19 who are at risk of developing complications. We have shown that inhaled therapies can be safely delivered at home, without the need for the patients, nurses or doctors to travel. Following the promising results from the SG016 Hospital Study, we are excited to see whether we can detect important benefits from early use of inhaled interferon beta (SNG001) for COVID-19 in the home environment, in terms of resolution of symptoms, preventing hospitalisation, and reducing the burden of Long-COVID.”

Professor Gareth Griffiths, Professor of Clinical Trials and Director of the NIHR Southampton Clinical Trials Unit, said:
“We were delighted to have supported Synairgen in running the home-setting arm of the SG016 trial, and to use our expertise in conducting clinical trials in a community setting. The innovative trial design meant that patients with COVID-19 were able to take part in the study from their own homes, with full support provided by the trial team, and finding evidence for treatments in this setting is a vital step forward in our fight against diseases such as COVID-19.”

In addition to The Lancet Respiratory Medicine publication, there is a growing body of evidence to support use of interferon beta in the context of COVID-19 infection as evidenced in the recent publication in Nature Genetics, following research carried out by the University of Southampton and published here.


References

  1. The Lancet Respiratory Medicine“Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial”. Monk, P D PhD, et al., 12 November 2020, accessible here.
  2. Nature Genetics: “A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection”. 11 January 2021, accessible


    here


    .

Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith
Tel: +44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs
[email protected]
Tel: +44 (0) 20 3709 5700


Notes for Editors

About Synairgen

Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. 

Synairgen’s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

SNG001 (inhaled Interferon beta) applicability to COVID-19

Interferon beta (‘IFN-beta’) is a naturally-occurring protein, which orchestrates the body’s antiviral responses. It is used widely in the treatment of multiple sclerosis and is a safe and well tolerated drug. There is growing evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility in ‘at-risk’ patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2, have evolved mechanisms which suppress endogenous IFN-beta production, helping the virus to evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells in vitro either prevents or greatly reduces viral replication, potentially reducing the severity of infection and accelerating recovery. Synairgen’s SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. It is pH neutral, and is free of mannitol, arginine and human serum albumin, making it suitable for inhaled delivery direct to the site of action. Phase I and II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 patients to-date.

In July 2020, Synairgen announced the results of its Phase II double-blind, placebo-controlled study of 101 randomised COVID-19 hospitalised patients, which showed that SNG001 given for 14 days was associated with greater odds of improvement versus placebo on the WHO Ordinal Scale for Clinical Improvement and more rapid recovery to the point where patients were no longer limited in their activity, with a greater proportion of patients recovering during the 28-day study period.

The results were published in The Lancet Respiratory Medicine: “Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial”. Monk, P D PhD, et al., 12 November 2020, accessible here.

About Southampton Clinical Trials Unit

The Southampton Clinical Trials Unit (CTU) is a National Institute for Health Research (NIHR) supported CTU with expertise in the design, conduct and analysis of interventional clinical trials. The CTU is based within the University of Southampton with offices at the University Hospital Southampton NHS Foundation Trust Southampton General Hospital site. (www.southampton.ac.uk/ctu/index.page